Recent Updates
Recently added Catalysts
JATT Positive Sentiment Score: 70/100

JATT II Acquisition Corp Announces Pricing of $60,000,000 Initial Public Offering Westfield, New Jersey, United States

Key Takeaway: JATT II Acquisition Corp has announced the pricing of its initial public offering, amounting to $60 million. The company will issue 6,000,000 ordinary shares at a price of $10.00 per share, and trading is set to begin on NASDAQ under the ticker symbol 'JATT' on April 17, 2026. The company, which is structured as a blank check firm, aims to focus its business combinations on healthcare and biotechnology. The IPO is subject to customary closing conditions and is scheduled to close on April 20, 2026.

Market Sentiment Analysis

POSITIVE FACTORS

  • JATT II Acquisition Corp has successfully priced its initial public offering (IPO) at $60 million.
  • The company intends to focus on healthcare and biotechnology sectors, potentially tapping into a lucrative market.
  • The IPO is expected to bolster the company's financial backing for future business combinations.

Full Press Release Details

JATT II Acquisition Corp Announces Pricing of
$60,000,000 Initial Public Offering
Westfield, New Jersey, United States, April
16, 2026 (GLOBE NEWSWIRE) - JATT II Acquisition Corp (the "Company"), a newly organized special purpose acquisition
company formed as a Cayman Islands exempted company, today announced the pricing of its initial public offering of 6,000,000 ordinary
shares at an offering price of $10.00 per ordinary share. The ordinary shares are expected to trade on the Nasdaq
Global Market ("NASDAQ") under the ticker symbol "JATT"
beginning April 17, 2026. The offering is expected to close on April 20, 2026, subject to customary closing conditions.
Securities, LLC is acting as sole book-running manager. The Company has granted the underwriters a 45-day option to purchase up to 900,000
additional ordinary shares at the initial public offering price to cover over-allotments, if any.
A registration statement relating to the securities
sold in the initial public offering was declared effective by the U.S. Securities and Exchange Commission (the "SEC") on April
16, 2026 (the "Effective Date"). The public offering is being made only by means of
a prospectus. When available, copies of the prospectus relating to the offering may be obtained from Guggenheim Securities, LLC, Attn:
Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About JATT II Acquisition Corp
JATT II Acquisition Corp is
a newly incorporated blank check company incorporated as a Cayman Islands exempted company and formed for the purpose of entering
into a merger, amalgamation, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination
with one or more businesses. The Company has not selected any specific business
combination target and has not, nor has anyone on its behalf, engaged in any substantive discussions, directly or indirectly, with any
business combination target with respect to an initial business combination with the Company. While the Company may pursue an initial
business combination in any business or industry, the Company intends to focus its search on healthcare and healthcare-related businesses,
with a primary emphasis on biotechnology and broader life sciences. In particular, the Company intends to seek businesses that can benefit
from the clinical, scientific, operational, strategic and capital markets experience of the management team and board of directors and,
in many cases, from access to the public markets as a means of funding continued development, executing strategic transactions and increasing
visibility with investors and potential partners. The Company expects to focus particularly, though not exclusively, on businesses applying
data-driven approaches, including machine learning, computational biology, structure-based drug design and related technologies, to improve
the therapeutic discovery and development process. The Company is sponsored by JATT Ventures II L.P. and is led by Dr. Someit Sidhu, Chief
Executive Officer and Chairman of the Board, and Nicholas Fernandez, Chief Financial Officer. The Company's Board of Directors also
includes Verender S. Badial, Arjun Goyal, Jonathon Kluft and Christopher Staral, bringing extensive experience across biotechnology investing,
company architecture, and public and private capital markets.
Forward-Looking Statements
This press release contains statements that constitute
"forward-looking statements," including with respect to the Company's initial public offering ("IPO") including
the gross proceeds of the IPO, the anticipated use of the net proceeds from the IPO and the search for an initial business combination.
No assurance can be given that the offering discussed above will be completed on the terms described, or that the net proceeds of the
offering will be used as indicated or that the Company will ultimately complete a business combination transaction in the sectors it is
targeting or at all. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of JATT II Acquisition
Corp, including those set forth in the Risk Factors section of JATT II Acquisition Corp's registration statement and preliminary
prospectus for the IPO filed with the SEC. Copies are available on the SEC's website, www.sec.gov. JATT II Acquisition Corp undertakes
no obligation to update these statements for revisions or changes after the date of this release, except as required by law.
Chief Financial Officer

Frequently Asked Questions

What is the price of JATT II Acquisition Corp's IPO?

The IPO is priced at $10.00 per ordinary share.

When does JATT II Acquisition Corp's shares begin trading?

The shares are expected to start trading on April 17, 2026.

Who is managing the IPO for JATT II Acquisition Corp?

Guggenheim Securities, LLC is the sole book-running manager for the IPO.

What industries will JATT II Acquisition Corp focus on?

The company aims to target healthcare, particularly in biotechnology and life sciences.

How many shares are being offered in the IPO?

The IPO offers a total of 6,000,000 ordinary shares.

Last updated: Apr 16, 2026